Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last C$0.53 CAD
Change Today +0.02 / 3.92%
Volume 177.5K
MBX On Other Exchanges
As of 4:10 PM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

microbix biosystems inc (MBX) Snapshot

Previous Close
Day High
Day Low
52 Week High
11/20/14 - C$0.90
52 Week Low
05/27/14 - C$0.35
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

microbix biosystems inc (MBX) Related Businessweek News

No Related Businessweek News Found

microbix biosystems inc (MBX) Details

Microbix Biosystems Inc. develops, manufactures, and sells biological products and technologies in North America, Europe, and internationally. The company manufactures and sells cell culture-based biological products, as well as infectious disease antigens. It offers infectious disease antigens, such as viral, bacterial, and parasitic products used in various applications, including immunodiagnostic assays; basic and applied research in virology, microbiology, cell biology, molecular biology, immunology, and pathology; as controls and calibrators for a range of medical devices; and for vaccine and antiviral research and development. In addition, the company provides adenovirus vectors, cells, and services to biopharmaceutical and biotechnology researchers and companies, as well as provides facility, technical, and production personnel for contract research and development. Its pipeline of technologies and products includes LumiSort semen sexing technology for the livestock industries; Kinlytic, a thrombolytic drug with various approved and potential applications, including the treatment of life-threatening blood clots, and VIRUSMAX, a proprietary technology for increasing virus yields in the manufacture of influenza vaccine. The company offers products for human health applications, namely in the vaccine, therapeutic, and diagnostic markets, as well as animal reproductive markets. Microbix Biosystems Inc. was founded in 1988 and is headquartered in Mississauga, Canada.

Founded in 1988

microbix biosystems inc (MBX) Top Compensated Officers

Chief Executive Officer, President, Director,...
Total Annual Compensation: C$217.0K
Founder, Executive Chairman, Member of Audit ...
Total Annual Compensation: C$190.9K
Chief Financial Officer
Total Annual Compensation: C$190.8K
Senior Vice President of Sales & Business Dev...
Total Annual Compensation: C$174.8K
Vice President of Biopharmaceuticals
Total Annual Compensation: C$150.7K
Compensation as of Fiscal Year 2014.

microbix biosystems inc (MBX) Key Developments

Microbix Biosystems Inc. Signs Distribution Agreement with Kim & Friends, Inc

Microbix Biosystems Inc. announced that it has signed an exclusive distribution agreement with Kim & Friends, Inc. The agreement provides Microbix with improved access to the key South Korean market for its virology products.

Microbix Biosystems Inc. Enters into Long-Term Agreement with Microbiologics, Inc

Microbix Biosystems Inc. entered into a long-term agreement with Microbiologics Inc. ('Microbiologics') pursuant to which Microbix will provide specialized viral material which will be incorporated into a line of full process controls, including instrument-specific sets, under Microbiologics' Helix EliteTM Molecular Standards brand.

Microbix Announces New Product Launches in Field of Molecular Diagnostics

Microbix Biosystems Inc. announced new Molecular Diagnostics ("MDx") product launches and provided an update on several important initiatives in its Virology Products business. Microbix has recently launched its first new products in the rapidly growing Molecular Diagnostics quality control market and has already booked sales to customers responsible for institutional accreditation testing. The Company is also preparing to sell these products directly to clinical laboratories, with a launch at industry trade shows in the spring. In addition, Microbix is in advanced development of two MDx control panels that will be used to test for sexually transmitted diseases and for gastrointestinal pathogens. These new MDx products will be launched in the second half of 2015 and target high volume markets that are expected to exceed 40 million tests in 2015 and grow at 10% annually as MDx testing becomes more widely adopted. Capping off these new planned product launches will be MDx control panels to test for respiratory pathogens and tropical diseases, all potentially large markets for Microbix MDx control products. To support the launch of its new MDx product line, Microbix is developing social media tools to create an awareness campaign using Facebook and LinkedIn.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MBX:CN C$0.53 CAD +0.02

MBX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MBX.
View Industry Companies

Industry Analysis


Industry Average

Valuation MBX Industry Range
Price/Earnings 100.0x
Price/Sales 4.6x
Price/Book 3.7x
Price/Cash Flow 731.4x
TEV/Sales 3.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MICROBIX BIOSYSTEMS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at